3SBio (HK:1530)
:1530
Want to see HK:1530 full AI Analyst Report?
Top Page
3SBio
(1530)
Select Model
Select Model
Rating:79Outperform
Price Target:
HK$22.00
▼(-12.91% Downside)
Action:Upgraded
Date:05/03/26
The score is driven primarily by very strong 2025 financial performance and a highly attractive valuation (very low P/E). Offsetting these positives, technical indicators show muted/weak momentum with price below key moving averages and a slightly negative MACD, and the sustainability of the 2025 step-change remains the main fundamental risk.
Positive Factors
2025 Revenue and Profitability Step‑Change
A near-90% revenue surge in 2025 alongside very high gross (~92%), operating (~60%) and net (~48%) margins materially boosts internal funding capacity. Sustained higher scale and margin profile supports reinvestment in R&D, manufacturing scale-up and stronger commercial execution over the medium term.
Negative Factors
Sustainability of 2025 Step‑Change
The large 2025 step-up may reflect timing or one-off drivers; historical swings in revenue and margins across 2022–2024 indicate execution or product‑mix sensitivity. If the 2025 dynamics do not persist, earnings and cash flow could revert materially, raising medium‑term predictability risk.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Revenue and Profitability Step‑Change
A near-90% revenue surge in 2025 alongside very high gross (~92%), operating (~60%) and net (~48%) margins materially boosts internal funding capacity. Sustained higher scale and margin profile supports reinvestment in R&D, manufacturing scale-up and stronger commercial execution over the medium term.
Read all positive factors
3SBio (1530) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$48.93B
Dividend Yield0.95%
Average Volume (3M)31.12M
Price to Earnings (P/E)6.3
Beta (1Y)0.87
Revenue Growth95.27%
EPS Growth304.20%
CountryHK
Employees5,577
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.41
Shares Outstanding2,538,039,300
10 Day Avg. Volume32,899,411
30 Day Avg. Volume31,124,824
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$35.03Price Target Upside38.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.07
Revenue Forecast (FY)HK$10.31B
3SBio Business Overview & Revenue Model
Company Description
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-in...
How the Company Makes Money
3SBio primarily makes money by selling prescription pharmaceuticals—especially biologic drugs—into the Chinese healthcare market. Its core revenue stream is product sales: the company manufactures and commercializes its own branded medicines (incl...
3SBio Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
84
Very Positive
Cash Flow
88
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.70B | 9.11B | 7.82B | 6.86B | 6.38B |
| Gross Profit | 16.35B | 7.83B | 6.64B | 5.67B | 5.28B |
| EBITDA | 11.00B | 2.93B | 2.53B | 2.75B | 2.26B |
| Net Income | 8.48B | 2.09B | 1.55B | 1.92B | 1.65B |
Balance Sheet | |||||
| Total Assets | 36.27B | 24.21B | 23.63B | 21.99B | 19.21B |
| Cash, Cash Equivalents and Short-Term Investments | 19.73B | 5.79B | 5.99B | 7.01B | 4.70B |
| Total Debt | 2.62B | 3.55B | 4.84B | 4.52B | 2.63B |
| Total Liabilities | 5.82B | 6.18B | 7.11B | 6.59B | 4.55B |
| Stockholders Equity | 27.22B | 15.44B | 14.03B | 12.96B | 12.23B |
Cash Flow | |||||
| Free Cash Flow | 9.13B | 2.24B | 1.38B | 1.21B | 432.57M |
| Operating Cash Flow | 9.67B | 3.20B | 2.08B | 2.18B | 1.58B |
| Investing Cash Flow | -1.83B | -1.36B | -1.35B | -3.72B | -1.29B |
| Financing Cash Flow | 2.35B | -2.25B | -352.98M | 763.22M | -481.12M |
3SBio Technical Analysis
Negative
25.26
Price Trends
22.51
Negative
23.43
Negative
26.88
Negative
Market Momentum
-0.98
Positive
32.34
Neutral
5.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1530, the sentiment is Negative. The current price of 25.26 is above the 20-day moving average (MA) of 21.69, above the 50-day MA of 22.51, and below the 200-day MA of 26.88, indicating a bearish trend. The MACD of -0.98 indicates Positive momentum. The RSI at 32.34 is Neutral, neither overbought nor oversold. The STOCH value of 5.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1530.
3SBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | HK$48.93B | 6.33 | 38.42% | 0.95% | 95.27% | 304.20% | |
73 Outperform | HK$38.67B | ― | 25.67% | ― | 16.65% | 0.87% | |
64 Neutral | HK$137.23B | 24.33 | 10.55% | ― | 16.79% | 47.14% | |
56 Neutral | HK$65.25B | 36.25 | 32.32% | ― | 80.08% | ― | |
53 Neutral | HK$105.93B | -43.30 | -14.26% | ― | 44.03% | -108.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$39.90B | -256.36 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1530
3SBio
19.28
-1.40
-6.78%
HK:2269
Wuxi Biologics (Cayman)
33.14
8.44
34.17%
HK:9926
Akeso, Inc.
115.00
27.10
30.83%
HK:9995
RemeGen Co. Ltd. Class H
85.80
38.90
82.94%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
23.16
6.22
36.72%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
71.15
27.65
63.56%
3SBio Corporate Events
3SBio Shareholders Back Spin-Off Dividend of Mandi Inc. Shares
Apr 23, 2026
3SBio shareholders have approved an ordinary resolution at an extraordinary general meeting held on 23 April 2026 to distribute all shares of subsidiary Mandi Inc. as a conditional special dividend in specie. The vote, overseen by Computershare Ho...
3SBio Calls Extraordinary Meeting to Approve Mandi Spin-Off Dividend
Apr 1, 2026
3SBio Inc. has called an extraordinary general meeting for 23 April 2026 in Shenyang to seek shareholder approval for a conditional special dividend in the form of a distribution in specie of all the shares it holds in subsidiary Mandi Inc. to qua...
3SBio Proposes HKD 0.25 Final Dividend for 2025 Financial Year
Mar 30, 2026
3SBio Inc. has proposed a final ordinary cash dividend of HKD 0.25 per share for the financial year ended 31 December 2025, underscoring its intention to return cash to shareholders. The dividend, subject to shareholder approval on 25 June 2026, w...
3SBio Plans Conditional Spin-Off Dividend via Mandi Inc. Share Distribution
Mar 30, 2026
3SBio has declared a conditional special dividend to shareholders, to be implemented via a distribution in specie of all the shares it holds in its subsidiary Mandi Inc. The distribution will allocate Mandi shares proportionally to qualifying 3SBi...
3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady
Mar 30, 2026
3SBio reported a sharp acceleration in growth for the year ended 31 December 2025, with revenue almost doubling to RMB17.70 billion and gross profit climbing 108.8% to RMB16.35 billion, supporting a gross margin of 92.4%. Net profit attributable t...
3SBio Sets March Board Meeting to Approve 2025 Results and Weigh Mandi Spin-Off Payout
Mar 17, 2026
3SBio Inc. has scheduled a board meeting for 30 March 2026 to review and approve its annual results for the year ended 31 December 2025, as well as to consider the declaration of a final dividend. The timing of the meeting signals that investors m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.